- Home
- MIRM vs EQX Comparison
MIRM vs EQX Comparison
Compare MIRM & EQX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MIRM
- EQX
- Stock Information
- Founded
- MIRM 2018
- EQX 2007
- Country
- MIRM United States
- EQX Canada
- Employees
- MIRM N/A
- EQX N/A
- Industry
- MIRM Biotechnology: Pharmaceutical Preparations
- EQX Precious Metals
- Sector
- MIRM Health Care
- EQX Basic Materials
- Exchange
- MIRM Nasdaq
- EQX Nasdaq
- Market Cap
- MIRM 2.5B
- EQX 2.7B
- IPO Year
- MIRM 2019
- EQX N/A
- Fundamental
- Price
- MIRM $52.45
- EQX $6.82
- Analyst Decision
- MIRM Strong Buy
- EQX
- Analyst Count
- MIRM 11
- EQX 0
- Target Price
- MIRM $57.00
- EQX N/A
- AVG Volume (30 Days)
- MIRM 504.4K
- EQX 8.0M
- Earning Date
- MIRM 02-26-2025
- EQX 02-19-2025
- Dividend Yield
- MIRM N/A
- EQX N/A
- EPS Growth
- MIRM N/A
- EQX 733.33
- EPS
- MIRM N/A
- EQX 0.75
- Revenue
- MIRM $307,028,000.00
- EQX $1,514,120,000.00
- Revenue This Year
- MIRM $83.04
- EQX $47.03
- Revenue Next Year
- MIRM $27.22
- EQX $52.06
- P/E Ratio
- MIRM N/A
- EQX $9.09
- Revenue Growth
- MIRM 112.14
- EQX 39.14
- 52 Week Low
- MIRM $23.14
- EQX $3.95
- 52 Week High
- MIRM $54.23
- EQX $7.22
- Technical
- Relative Strength Index (RSI)
- MIRM 64.07
- EQX 57.65
- Support Level
- MIRM $51.02
- EQX $6.38
- Resistance Level
- MIRM $53.76
- EQX $7.22
- Average True Range (ATR)
- MIRM 2.04
- EQX 0.31
- MACD
- MIRM 0.03
- EQX 0.00
- Stochastic Oscillator
- MIRM 73.31
- EQX 65.52
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter "IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.
About EQX Equinox Gold Corp.
Equinox Gold Corp is a mining company engaged in the operation, acquisition, exploration and development of mineral properties, with a focus on gold. Equinox Gold has around seven operating gold mines and a clear plan to increase production by advancing pipeline of growth projects.